drugset
drugset / Trial / NCT04208646

Allogenic Adipose Tissue-Derived Mesenchymal Progenitor Cells for the Treatment of Knee Osteoarthritis

NCT04208646 ↗

Phase 2 Completed 106 enrolled Shanghai AbelZeta Ltd. China-Japan Friendship Hospital · collabHuashan Hospital · collabRenJi Hospital · collabSecond Affiliated Hospital, School of Medicine, Zhejiang University · collabShanghai 6th People's Hospital · collabShanghai General Hospital, Shanghai Jiao Tong University School of Medicine · collabShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

Evaluate the efficacy and safety of Allogenic Adipose Tissue-Derived Mesenchymal Progenitor Cells Therapy

Timeline

Start
2020-05-16
Primary completion
2021-06-30
Completion
2023-07-31

Drugs

EvaluationDrugModalityDoseRoute
Subject AlloJoin® Cell therapy — Other

Indications

osteoarthritis, knee